Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain.

Lele Zhao,D. Cao,Tiantian Chen,Ying-Qing Wang,Z. Miao,Yechun Xu,Wu-yan Chen,Xin Wang,Yanlian Li,Z. Du,B. Xiong,Jian Li,Chunyan Xu,Naixia Zhang,Jianhua He

DOI: https://doi.org/10.1021/jm301793a

IF: 8.039

2013-05-14

Journal of Medicinal Chemistry

Abstract:Recognizing acetyllysine of histone is a vital process of epigenetic regulation that is mediated by a protein module called bromodomain. To contribute novel scaffolds for developing into bromodomain inhibitors, we utilize a fragment-based drug discovery approach. By successively applying docking and X-ray crystallography, we were able to identify 9 fragment hits from diffracting more than 60 crystals. In the present work, we described four of them and carried out the integrated lead optimization for fragment 8, which bears a 2-thiazolidinone core. After several rounds of structure guided modifications, we assessed the druggability of 2-thiazolidinone by modulating in vitro pharmacokinetic studies and cellular activity assay. The results showed that two potent compounds of 2-thiazolidinones have good metabolic stability. Also, the cellular assay confirmed the activities of 2-thiazolidinones. Together, we hope the identified 2-thiazolidinone chemotype and other fragment hits described herein can stimulate researchers to develop more diversified bromodomain inhibitors.